Quick summary
Nesfatin-1 is an 82-amino acid satiety peptide from nucleobindin-2 that suppresses food intake via leptin-independent central mechanisms. It activates oxytocin neurons and melanocortin signaling; levels are altered in obesity.
Overview
Nesfatin-1 is an 82-amino acid satiety peptide derived from the N-terminal region of the 396-amino acid precursor protein nucleobindin-2 (NUCB2). Discovered in 2006, it is expressed in the hypothalamus, brainstem, and peripheral tissues including the stomach and adipose tissue. Central nesfatin-1 potently suppresses food intake in a leptin-independent manner, making it a research target for obesity and metabolic disease.
Mechanism of action
Nesfatin-1 exerts anorexigenic effects predominantly through central (hypothalamic and brainstem) mechanisms. Intracerebroventricular injection suppresses food intake dose-dependently by activating oxytocin neurons in the paraventricular nucleus and modulating melanocortin signaling. Nesfatin-1 also acts on the melanocortin-3/4 receptor system downstream. Peripherally, it is released postprandially from gastric X/A-like cells and may function as a gut-derived satiety signal. Its receptor has not been definitively identified, though GPR3 and NPY-related receptors have been proposed.
Dosing protocols
| Purpose | Route | Dosage | Frequency | Notes |
|---|---|---|---|---|
| appetite suppression research (animal) | intravenous | 0.5–5 nmol | per experimental session (ICV preferred in animal models) |
Dosing information is for educational purposes only. Consult a qualified healthcare professional before using any peptide.
Research summary
Since its discovery in 2006, nesfatin-1 research has grown substantially. Animal studies consistently show that central nesfatin-1 reduces food intake and body weight gain, and that neutralizing antibodies stimulate appetite. Plasma nesfatin-1 levels are altered in obesity, anorexia nervosa, and type 2 diabetes in human studies. Preclinical research suggests cardioprotective effects against ischemia-reperfusion injury. No human interventional trials have been conducted. The receptor and downstream signaling cascade remain incompletely characterized.[1][2][3][4]
Evidence grading
Each claimed benefit is graded by the strength of available evidence. Grades reflect study quality, not effect size.
Strong = multiple RCTs · Moderate = limited trials or observational · Preliminary = animal or in vitro only · Insufficient = anecdotal or no published data
Side effects
Side effects vary by individual. This is not an exhaustive list. Report unusual symptoms to a healthcare professional.
Common stacks
Peptides commonly paired with Nesfatin-1 for synergistic effects.
Legal status
Nesfatin-1 is available for laboratory research only and has no approved clinical applications. It has not advanced to clinical trials in humans.
Sourcing & access
Research compound
Nesfatin-1 is classified as a research compound. Regulatory status varies by jurisdiction. Always verify current legal status and source from vendors providing third-party certificates of analysis (COA).
Frequently asked questions
Nesfatin-1 is an 82-amino acid satiety peptide derived from the N-terminal region of nucleobindin-2 (NUCB2). Discovered in 2006, it is expressed in the hypothalamus, brainstem, stomach, and adipose tissue, and suppresses food intake independently of leptin signaling.
Nesfatin-1 exerts anorexigenic effects by activating oxytocin neurons in the paraventricular nucleus and modulating melanocortin-3/4 receptor signaling in the hypothalamus. Peripherally, it is released postprandially from gastric cells and may function as a gut-derived satiety signal. Its receptor has not been definitively identified.
Nesfatin-1 has not been tested in human interventional trials, so its safety profile in humans is unknown. Animal studies note reduced locomotor activity at high doses. Plasma nesfatin-1 levels are altered in obesity, anorexia nervosa, and type 2 diabetes.
Nesfatin-1 suppresses food intake through leptin-independent pathways, making it a research target for obesity in patients with leptin resistance. Central administration consistently reduces food intake and body weight gain in animals, and neutralizing antibodies stimulate appetite, confirming its physiological relevance.
Research references
- Nesfatin-1: a novel satiety peptide regulating energy homeostasis and food intakePubMed
- Nesfatin-1 effects on the hypothalamic-pituitary-adrenal axis and stress responsePubMed
- Nesfatin-1 in metabolic regulation: cardiovascular and glucose homeostasis effectsPubMed
- Central and peripheral nesfatin-1 actions on appetite and body weightPubMed